{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:09:30Z","timestamp":1792681770267,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":276,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008081","name":"Dystrophic Epidermolysis Bullosa Research Association","doi-asserted-by":"publisher","award":["Mellerio 1"],"award-info":[{"award-number":["Mellerio 1"]}],"id":[{"id":"10.13039\/100008081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin fragility disorder requiring multidisciplinary management. Information regarding costs of current standard treatment is scant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>As part of a longitudinal natural history study, we explored the community care costs of UK patients with different forms of RDEB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty-nine individuals with RDEB provided detailed information on multiple facets of RDEB including disease severity scores (iscorEB, BEBS) and patient reported outcomes (quality of life evaluation in epidermolysis bullosa, iscorEB patient questionnaire). Costs data included time spent doing dressings, frequency of dressing changes, details of materials used, and paid and unpaid care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall costs of dressing materials and associated care were high in RDEB. Median annual costs across all subtypes for those using dressings (n = 51) were over \u00a326 000. For severe RDEB (RDEB-S), median costs were almost \u00a390 000 per annum, with a median of 18 h per week spent on dressing changes. Half of working-age adults with RDEB were unemployed and 39% of carers were unable to take on full-time or part-time paid employment, adding to indirect costs and the financial burden from RDEB on families and society.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings demonstrate the high costs of care of RDEB, particularly for RDEB-S. The current expense supports the drive to develop new therapies which accelerate wound healing and diminish total wound burden, thereby reducing costs of dressings and care. While costly to bring to market, these might ultimately reduce the overall cost of treatment and also the impact on individuals living with this rare disease. The data also highlight the need for adequate reimbursement for EB care which can place significant financial strain on families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ski2.314","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T02:10:55Z","timestamp":1704939055000},"source":"Crossref","is-referenced-by-count":9,"title":["Costs of UK Community Care for Individuals with Recessive Dystrophic Epidermolysis Bullosa: Findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study"],"prefix":"10.1093","volume":"4","author":[{"given":"Eunice","family":"Jeffs","sequence":"first","affiliation":[{"name":"St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pillay","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesedi","family":"Ledwaba-Chapman","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bisquera","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Robertson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Royal Children's Hospital , Parkville ,, Victoria ,","place":["Australia"]},{"name":"Department of Dermatology, Royal Melbourne Hospital , Melbourne ,, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King's College London, Faculty of Life Sciences and Medicine , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Great Ormond Street Hospital for Children , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Patel","sequence":"additional","affiliation":[{"name":"Anita Patel Health Economics Consulting Ltd , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemima","family":"Mellerio","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, King's College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"4","key":"2025112510514025200_ski2314-bib-0001","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/jdv.17012","article-title":"Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?","volume":"35","author":"Baardman","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2025112510514025200_ski2314-bib-0002","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjd.20958","article-title":"The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database","volume":"186","author":"Petrof","year":"2022","journal-title":"Br J Dermatol"},{"issue":"11","key":"2025112510514025200_ski2314-bib-0003","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","article-title":"Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis bullosa registry","volume":"152","author":"Fine","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2025112510514025200_ski2314-bib-0004","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues","volume":"61","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2025112510514025200_ski2314-bib-0005","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs","volume":"61","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2025112510514025200_ski2314-bib-0006","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2025112510514025200_ski2314-bib-0007","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3875","article-title":"Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study","volume":"101","author":"Robertson","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"Suppl l","key":"2025112510514025200_ski2314-bib-0008","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10198-016-0783-4","article-title":"Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe","volume":"17","author":"Angelis","year":"2016","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2025112510514025200_ski2314-bib-0009","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","article-title":"Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study","volume":"17","author":"Angelis","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2025112510514025200_ski2314-bib-0010","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/medethics-2020-106978","article-title":"Rare diseases in healthcare priority setting: should rarity matter?","volume":"48","author":"Albertsen","year":"2022","journal-title":"J Med Ethics"},{"issue":"1","key":"2025112510514025200_ski2314-bib-0011","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13023-019-1199-x","article-title":"Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"14","author":"Connolly","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2025112510514025200_ski2314-bib-0012","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1111\/apa.15974","article-title":"Progress, challenges and global approaches to rare diseases","volume":"110","author":"Groft","year":"2021","journal-title":"Acta Paediatr"},{"key":"2025112510514025200_ski2314-bib-0013","author":"Orpan Drug Act","journal-title":"HR 5238, 97th Congress 1983 (enacted)"},{"issue":"5","key":"2025112510514025200_ski2314-bib-0014","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","article-title":"Economic modeling considerations for rare diseases","volume":"21","author":"Pearson","year":"2018","journal-title":"Value Health"},{"key":"2025112510514025200_ski2314-bib-0015","volume-title":"Regulation (European Parliament) 141\/2000 of 16 December 1999 on orphan medicinal products","year":"2000"},{"issue":"3","key":"2025112510514025200_ski2314-bib-0016","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18031101","article-title":"Reflections on the importance of cost of illness analysis in rare diseases: a proposal","volume":"18","author":"Armeni","year":"2021","journal-title":"Int J Environ Res Publ Health"},{"issue":"7","key":"2025112510514025200_ski2314-bib-0017","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","article-title":"Socio-economic burden of rare diseases: a systematic review of cost of illness evidence","volume":"119","author":"Angelis","year":"2015","journal-title":"Health Pol"},{"issue":"1","key":"2025112510514025200_ski2314-bib-0018","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-021-01815-3","article-title":"Cost-of-illness studies in rare diseases: a scoping review","volume":"16","author":"Garc\u00eda-P\u00e9rez","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2025112510514025200_ski2314-bib-0019","volume-title":"British national formulary (online)","author":"Joint Formulary Committee"},{"key":"2025112510514025200_ski2314-bib-0020","volume-title":"Wound care handbook 2020-2021","author":"Journal of Wound Care","year":"2020"},{"key":"2025112510514025200_ski2314-bib-0021","author":"NHS Business Services Authority","year":"2020","journal-title":"Approved list of appliances part IX, 01\/2020"},{"key":"2025112510514025200_ski2314-bib-0022","author":"NHS Employers","year":"2020","journal-title":"Annual pay scales 2020\/21"},{"issue":"1","key":"2025112510514025200_ski2314-bib-0023","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10198-003-0189-y","article-title":"Economic valuation of informal care. An overview of methods and applications","volume":"5","author":"van den Berg","year":"2004","journal-title":"Eur J Health Econ"},{"issue":"5","key":"2025112510514025200_ski2314-bib-0024","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/bjd.16627","article-title":"Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB)","volume":"178","author":"Bruckner","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"2025112510514025200_ski2314-bib-0025","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","article-title":"The Birmingham epidermolysis bullosa severity score: development and validation","volume":"160","author":"Moss","year":"2009","journal-title":"Br J Dermatol"},{"issue":"6","key":"2025112510514025200_ski2314-bib-0026","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","article-title":"Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument","volume":"161","author":"Frew","year":"2009","journal-title":"Br J Dermatol"},{"issue":"8","key":"2025112510514025200_ski2314-bib-0027","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3456","article-title":"Direct costs of epidermolysis bullosa by disease severity","volume":"100","author":"Flannery","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"2025112510514025200_ski2314-bib-0028","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","article-title":"Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa","volume":"17","author":"Feinstein","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2025112510514025200_ski2314-bib-0029","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/pde.14340","article-title":"Financial burden of epidermolysis bullosa on patients in the United States","volume":"37","author":"Gorell","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"2025112510514025200_ski2314-bib-0030","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","article-title":"The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers","volume":"15","author":"Bruckner","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2025112510514025200_ski2314-bib-0031","volume-title":"British national formulary","author":"Joint Formulary Committee","year":"2023","edition":"86th ed"},{"issue":"1","key":"2025112510514025200_ski2314-bib-0032","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/pde.12243","article-title":"Evaluation of wound care options in patients with recessive dystrophic epidermolysis bullosa: a costly necessity","volume":"31","author":"Kirkorian","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"2025112510514025200_ski2314-bib-0033","volume-title":"Best practice guidelines for skin and wound care in epidermolysis bullosa. An international consensus","author":"Denyer","year":"2017"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/1\/ski2.314\/59730116\/skinhd_4_1_e314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/1\/ski2.314\/59730116\/skinhd_4_1_e314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:51:49Z","timestamp":1764085909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.314\/7755688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.314","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,10]]},"article-number":"ski2.314"}}